Get the weekly dispatch.
Thanks — you're on the list.
Most coverage of rescheduling treats it as a tax story or a banking story. The research story is what would actually change for investigator-initiated science — and how much of the gap could be closed.
The voucher list does the talking. The same FDA that issued the Lykos CRL still issued the vouchers, and it sent them to programs whose methods it considers defensible. Sponsors who hear political acceleration as scientific accommodation will misread it as the field misread the original draft guidance, and pay the same kind of price.
Six days after Trump's executive order, the agency named three programs for one-to-two-month reviews. The picks reset the field's near-term hierarchy and confirm the methodological reasons the MDMA program is still on the outside.
An evergreen reference on what actually matters in a psychedelic-assisted therapy trial readout — blinding analyses, expectancy controls, dose-response designs, and the questions to ask before you trust the headline number.
Most coverage of rescheduling fixates on 280E tax relief. The bigger story is what happens to research registration, FDA pathway access, and the M&A market for MSOs that have been frozen out of institutional capital for a decade.
When the FDA approved zuranolone for postpartum depression but rejected it for major depressive disorder, it built a commercial trap that the company has been unable to escape. The lesson generalizes.
Direct-to-consumer mental health platforms built businesses on the difference between cash-pay convenience and insurance reimbursement complexity. That gap is closing on both sides at once.